Citi initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $42 price target The LDL cholesterol lowering market is “large and with substantial remaining unmet need,” the analyst tells investors in a research note. The firm says upwards of 75% of patients with atherosclerotic cardiovascular disease still need additional therapies to help reach their targeted LDL-C goal level, and the growth of the non-statin market has seen high double digit precent growth year-over-year since 2020. NewAmsterdam’s obicetrapib aims to be a first-in-class agent that would be an add-on to patients on statins to help address LDL-C levels, and with potential to be used in combination therapy with ezetimibe for those who need additional lipid lowering, contends Citi.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
- NewAmsterdam Pharma Schedules R&D Day for June 2025
- NewAmsterdam Pharma initiated with a Buy at Stifel
- Promising Alzheimer’s Drug Development Fuels Buy Rating for NewAmsterdam Pharma
- NewAmsterdam Pharma: Promising Growth Potential with Innovative Alzheimer’s Biomarker and LDL Reduction Strategies